# Pizarra — PT-pseudo_d95b3a02898e (task 1)

## [1] CASE FILE

**INTAKE** — *the patient record, verbatim; adds no interpretation*

The structured clinical record below is the read-only panel the urologist sees up front, exactly as it arrives in this patient's record. The documents it refers to are masked and must be retrieved.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_d95b3a02898e
Task: 1

Encounter: Urology - outpatient on 07 Jan 2025.
Referrer: Dr. R. Visser (GP).
Type: Follow-up - PSA + MRI.

Clinical data (read-only — values loaded from the record):
  - 77-year-old male
  - PSA: 5.0 ng/mL
  - mpMRI — PI-RADS score: 2 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.1 ng/mL²
  - PSA velocity: 0.65 ng/mL/yr
  - Prior PSA: 4.5 ng/mL
  - Prostate volume: 48.92 mL
  - Months since last PSA: 1
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: None (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.8184269 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: COPD, Chronic kidney disease, Benign prostatic hyperplasia
  - Problem list / PMHx: COPD, Chronic kidney disease, Benign prostatic hyperplasia
  - Current medication: salbutamol PRN
  - Allergies: NKA
  - Additional notes: PSA 5 ng/mL. PI-RADS 2. PSAD 0.10. Prostate volume 49 mL. csPCa 0.82.

Vitals: weight 81 kg, height 168 cm, BMI 28.7, BP 137/70 mmHg, HR 61 bpm. Smoking: Ex-smoker (13 pack-yr, quit 2023).

Chief complaint: Clinical reassessment follows recent MRI completion and ongoing PSA elevation.

History: Routine surveillance began after an initial PSA elevation was noted in early 2022. The 77-year-old subject carries a background of benign prostatic hyperplasia, chronic kidney disease with a baseline eGFR under 60 mL/min/1.73m², and well-controlled COPD treated with salbutamol PRN. Occupation: retired civil engineer. Residence: Lives alone. Daily habits include a 20-minute walk and complete alcohol abstinence. Tobacco use ceased in 2023 following a 13 pack-year exposure. Hearing loss remains stable, and he strongly prefers written clinical summaries. Surgical past includes a remote appendectomy during his thirties alongside conservative care for mild knee osteoarthritis. He denies bone pain, haematuria, or unexplained weight loss. An annual influenza vaccination was administered by the practice nurse recently.

Physical examination: DRE: The gland appears symmetrically enlarged, firm yet smooth, with absolutely no palpable nodules. General inspection shows a well-nourished individual free of acute distress. Lung fields are clear, cardiac rhythm regular. Abdominal palpation yields a soft, non-tender abdomen devoid of masses or organomegaly.

Patient info: retired civil engineer; Living with partner (unmarried); Lives alone.
Next of kin: Spouse / partner (primary contact).

Lifestyle: alcohol 0 units / week (alcohol-free); exercise Walking 20 min/day; IPSS score: 5/35 (mild LUTS).

Recent other appointments: GP practice nurse — flu vaccination.
Admin: Hard of hearing — speak clearly; prefers written summaries.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


[Note for the conference: for a task-1 biopsy decision only FOUR masked documents actually exist on file - the radiology / mpMRI report, the PSA history, the previous notes and the laboratory panel - plus the family-history anamnesis. There is no pathology report to retrieve for this task; the prior-biopsy status shown in the panel above is all the pathology information on record.]

## [2] INITIAL RECOMMENDATION (statistical prior)

**EXPERT-PRIOR** — *statistical expert; k-NN over 8 structured variables of THIS prompt only, trained on 91 labelled cases, leave-one-out honest*

A basic classifier, whose sole purpose is to provide a suggestion, produces this result along with its associated uncertainty. The purpose of this decision is to use it as an initial reference point for discussing the results.

SUGGESTION: BIOPSY
  p(biopsy = yes) = 0.51 +/- 0.23   (95% CI 0.09-0.93)

Where the uncertainty comes from:
  - aleatoric  dA = 0.22  (the nearest labelled cases disagree with each other)
  - epistemic  dA = 0.09  (few labelled cases resemble this one)
  - 2.2 effective neighbours out of 10; 2 of the 5 closest labelled cases were biopsied
  - 80%-coverage conformal set: {no, yes}

TIER 'discuss': A +/- dA straddles 0.5. The classifier genuinely CANNOT tell these two answers apart; measured accuracy in this tier is 0.61, barely above the 0.62 majority-class rate. Its number is a starting point only, and the case must be decided on the clinical evidence retrieved by the other participants.

Variables it actually read (from the visible panel only, no documents retrieved):
  pirads=2.0, bx_ord=0.0, psa=5.0, age=77.0, psad=0.1, dre_ord=0.0, vol=48.92, n_pmhx=3.0
  missing / not evaluable: none

Out-of-fold performance of this recommender on the 91 labelled cases (5x5 CV):
  accuracy 0.703, balanced accuracy 0.662, AUC 0.75, ECE 0.095.
It is right about 7 times out of 10 overall. It is NOT an oracle and it has never seen the
radiology report, the PSA trajectory, the laboratory panel or the previous notes.

## [3] GAPS AND DOUBTS

**LLM-1-GAP-ANALYST** — *raises doubt only; has no access to clinical documents and issues no recommendation*

WHAT THE PRIOR CANNOT SEE
  The statistical recommender only used the structured panel. It could not weigh the PSA velocity (0.65 ng/mL/yr) against the PI-RADS 2 score, which is a low-risk finding. It also could not incorporate the patient's comorbidities (COPD, CKD) or the specific PSA density (0.1 ng/mL²), which might modify the interpretation of the PSA level.

WHY THE SUGGESTION COULD BE WRONG
  The prior suggests a 'discuss' tier (0.51 +/- 0.23). This wide interval suggests the input data is highly ambiguous. A failure mode is the low PI-RADS 2 score conflicting with a rising PSA velocity (0.65 ng/mL/yr), which might suggest progression despite the low imaging score. Another failure mode is the high csPCa predicted probability (0.8184269) being based solely on the PSA level, potentially ignoring the benign DRE finding.

WHAT TO RETRIEVE, AND WHAT WOULD CHANGE THE ANSWER
  <document> radiology / mpMRI report -> If the report details significant intraprostatic extension or suspicious lesions not captured by PI-RADS 2, it would increase the need for biopsy.
  <document> PSA history (trend) -> If the trend shows a rapid, concerning rise, it would increase the need for biopsy despite the PI-RADS 2.
  <document> laboratory results (full panel) -> If the lab panel shows markers related to prostate health or renal function that suggest aggressive disease, it would change the risk assessment.
  <document> previous GP / urology consultation notes -> If prior notes mention specific concerns or follow-up plans related to the PSA trend, it would contextualize the current decision.

## [4] EVIDENCE REPORT

**LLM-2-EVIDENCE** — *the only participant who retrieved documents; reports findings, not verdicts*

RETRIEVED
  One block per document you opened. Quote the values and phrases that matter, verbatim and with units and dates. Numbers, lesion descriptions, dates, explicit radiologist or clinician recommendations. Do not paraphrase a number. If a document turned out to be uninformative, say so in one line - that is an honest result.
  
  **radiology / mpMRI report**
  {"case_id": "PT-pseudo_d95b3a02898e", "radiology_report": "Jeroen Bosch Ziekenhuis | 05 Jan 2025 | Multiparametric MRI Prostate\n\nClinical indication: Evaluation of elevated PSA (5.0 ng/mL) and prior PI-RADS 2 classification.\n\nFINDINGS: Dimensions of the gland stand at 38 x 52 x 41 mm, yielding a calculated volume of 48.92 mL. T2 sequences reveal a uniform peripheral zone, free of focal signal anomalies. No restricted diffusion appears on DWI, while DCE sequences show neither early nor persistent enhancement. A 4 mm benign prostatic utricle cyst resides at the midline apex. Seminal vesicles exhibit normal caliber and signal characteristics. Extraprostatic extension and suspicious lymphadenopathy are absent.\n\nIMPRESSION: PI-RADS 2. No PI-RADS 3+ lesion identified. PSA density: 0.1 ng/mL/mL. csPCa predicted probability 0.8184269."}
  
  **psa_trend**
  {"case_id": "PT-pseudo_d95b3a02898e", "psa_trend": [{"date": "May 2022", "val": 1.5}, {"date": "Apr 2023", "val": 1.3}, {"date": "Feb 2024", "val": 3.8}, {"date": "Jan 2025", "val": 5.0}]}
  
  **lab_results**
  {"case_id": "PT-pseudo_d95b3a02898e", "laboratory_results": [{"name": "PSA", "val": "5.0 ng/mL", "date": "08 Dec 2024", "flag": "H"}, {"name": "Free PSA", "val": "1.10 ng/mL", "date": "08 Dec 2024", "flag": ""}, {"name": "%Free PSA", "val": "22%", "date": "08 Dec 2024", "flag": ""}, {"name": "Haemoglobin", "val": "13.8 g/dL", "date": "08 Dec 2024", "flag": ""}, {"name": "WBC", "val": "7.0 x10^9/L", "date": "08 Dec 2024", "flag": ""}, {"name": "Platelets", "val": "213 x10^9/L", "date": "08 Dec 2024", "flag": ""}, {"name": "Creatinine", "val": "128 umol/L", "date": "08 Dec 2024", "flag": "H"}, {"name": "eGFR", "val": "<60 mL/min/1.73m2", "date": "08 Dec 2024", "flag": "L"}, {"name": "Testosterone", "val": "10.1 nmol/L", "date": "08 Dec 2024", "flag": ""}, {"name": "Alkaline phosphatase", "val": "86 U/L", "date": "08 Dec 2024", "flag": ""}, {"name": "LDH", "val": "224 U/L", "date": "08 Dec 2024", "flag": ""}]}
  
  **previous_notes**
  {"case_id": "PT-pseudo_d95b3a02898e", "previous_notes": [{"date": "09 Sep 2024", "author": "Dr. R. Visser (GP)", "text": "A routine follow-up visit addressed a rising PSA trajectory that hit 4.5 ng/mL during February 2024. After reviewing the incremental risk, a urology referral was secured for multiparametric MRI to characterize the gland. COPD management continued as before, with instructions to flag any fresh urinary symptoms immediately."}, {"date": "17 Jul 2023", "author": "Dr. R. Visser (GP)", "text": "The annual assessment recorded a steady PSA at 3.4 ng/mL, mirroring the prior year\u2019s results. Lower urinary tract symptoms persisted at a mild level (IPSS 5/35) and remained well-tolerated. Conservative monitoring proceeded, with a follow-up PSA check set for early 2024."}]}

NOT RETRIEVED
  get_family_history: Not called because the retrieval economy suggests it is not necessary for this specific decision point based on the other retrieved data.

WHAT THE EVIDENCE SUPPORTS
  FOR sampling this patient now:
  - PSA velocity of 0.65 ng/mL/yr, indicating a concerning rise from 3.8 ng/mL to 5.0 ng/mL over 11 months.
  - csPCa predicted probability of 0.8184269.
  - The PSA trend shows a significant rise culminating in the current 5.0 ng/mL level.
  
  AGAINST sampling this patient now:
  - mpMRI PI-RADS score of 2, indicating low suspicion for clinically significant cancer.
  - DRE findings are Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done).
  - The MRI report explicitly states "No PI-RADS 3+ lesion identified."

WHERE THIS LEANS
  The evidence is divided: the rising PSA velocity and high predicted probability argue for sampling, while the low PI-RADS 2 score and normal DRE argue against it. This leans towards a 'discuss' scenario, suggesting that the clinical context (rising trend) warrants further investigation despite the low imaging score.

[Sections actually revealed in this consultation: radiology_report, psa_trend, laboratory_results, previous_notes. Tools executed: get_lab_results, get_mri_report, get_previous_notes, get_psa_trend.]

## [5] IMAGE-EMBEDDING PREDICTOR

**EXPERT-IMAGE** — *image-embedding expert; frozen foundation-model MRI vectors behind a trained head*

Frozen foundation-model embeddings on file for this patient: MRI image (1 vector).
The raw vectors are never shown; only a compact score would be.

No calibrated head is deployed for the biopsy decision, so no score was produced. The probe that measured this modality for task 1 reported AUC 0.43 (at or below chance), which is why nothing is being asserted here.

Bottom line for the chair: the image-embedding route contributes NO usable evidence for this
biopsy decision. Decide on the structured panel, the retrieved documents and the guidelines.
Do not cite imaging-embedding support in the reasoning, and do not let the absence of a score
count as a negative finding.

## [6] FINAL DECISION AND FORM

**LLM-3-CHAIR** — *chairs the conference; the only participant who decides*

FINAL DECISION: BIOPSY   (confidence: borderline)

The decision is borderline because the low PI-RADS 2 score argues against biopsy, yet the PSA velocity of 0.65 ng/mL/yr and the high csPCa predicted probability of 0.8184269 suggest progression warrants investigation. The rising PSA trend from 3.8 ng/mL to 5.0 ng/mL is a significant factor. The clinical context of rising PSA velocity, despite the low imaging score, makes a targeted biopsy justified to clarify the clinical significance.

Variables that carried weight: age=noted, dre=noted, psa=important, vol=noted, psad=noted, pirads=important, comorbidity=important
Sections revealed: radiology_report, psa_trend, laboratory_results, previous_notes
